SURMOUNT-5: The First Direct Head-to-Head Trial For years, comparing tirzepatide weight loss results to semaglutide weight loss results required inferring from separate trials run in different patient groups
Methods 202, 182191
Both agents promoted weight loss (SGLT2i: standardized mean difference -0.59
Narayana, President, SEAR Pharm Forum, President Indian Pharmaceutical Association - India Facilitator: -Manisha Shridhar, Regional Advisor, IPR, Trade&Health, WHO-SEARO - India Speakers: - Manjiri Gharat, FIP Vice-President, Vice-President of Indian Pharmaceutical Association (IPA) and Chairperson of IPA Comm.Ph.Division
Warnings: Individuals with hypersensitivity to NAD+ or any excipients should avoid use
The service price is economical